Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1206 vs Xgeva in patients with bone metastases from solid tumors
CTR20191911Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2019
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of QL1206 in bone metastases, sponsored by Qilu Pharmaceutical. Started Oct 2019; status: completed.
02
Drugs
QL1206
03
Conditions
bone metastases
Beyond the preview
Go deeper on CTR20191911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191911.